<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532439</url>
  </required_header>
  <id_info>
    <org_study_id>1408063</org_study_id>
    <nct_id>NCT02532439</nct_id>
  </id_info>
  <brief_title>Bone Microarchitectural Database Constitution From HR-pQCT Device in Clinical Situation Potentially Associated With Bone Loss</brief_title>
  <acronym>DMPOs</acronym>
  <official_title>Bone Microarchitectural Database Constitution From High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Device in Clinical Situation Potentially Associated With Bone Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bone fracture occurrence is associated with an increasing of morbidity and mortality. Some
      factors of fracture occurrence have been highlighted. For example, some diseases or therapy
      are known to increased risk of bone fracture only in some patients. Accordingly, it is
      important for clinicians to identify patients at risk for bone fracture. Right now, various
      tools are available for the clinicians:

        -  clinical exam,

        -  bone mineral density assessed by Dual Energy X-ray Absorptiometry (DEXA),

        -  an algorithm based on interrogation, clinical exam and bone mineral density. However,
           prediction of bone fracture risk needs to be improved since only 50% of bone fractures
           can be predicted. DEXA provides information for fracture risk estimation, but it is
           unable to distinguish cortical part to trabecular part. It also fails to quantify the
           microstructural properties that influence bone strength. Bone microarchitecture,
           including the cortical compartment can now be assessed in vivo by the HR-pQCT. This
           technique allows access to several parameters: on the one hand the volumetric bone
           mineral density for the whole area measured as well as cortical and trabecular regions,
           and on the other hand, the thickness and cortical porosity and the number of trabecular,
           their orientation and distribution.

      Thus, the HR-pQCT allows realizing a virtual bone biopsy and provides information on cortical
      and trabecular bone microarchitecture. This is the only noninvasive way to assess cortical
      and trabecular bone microarchitecture.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone microarchitecture parameter</measure>
    <time_frame>Day 1</time_frame>
    <description>Compare between patient group and control group bone microarchitecture parameter.
Different bone microarchitecture parameter is a composite outcome assessed by HR-pQCT : Total volumetric mineral density (mg/ccm HA), Trabecular volumetric mineral density (mg/ccm HA), Cortical volumetric mineral density (mg/ccm HA), Trabecular number ((1/mm), Trabecular thickness (mm), Cortical thickness (mm), Trabecular separation (mm), Cortical porosity (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone density</measure>
    <time_frame>day 1</time_frame>
    <description>Bone density is a composite outcome measured with two devices HR-pQCT and DEXA. Parameters measured with HR-pQCT are : Total volumetric mineral density (mg/ccm HA), Trabecular volumetric mineral density (mg/ccm HA) and Cortical volumetric mineral density (mg/ccm HA).
Parameter measured by DEXA is Bone Mineral Density (BMD, g/cm2)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Bone Loss</condition>
  <arm_group>
    <arm_group_label>Patient group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measure bone quality and quantity with HR-pQCT and DEXA of patient group Patient group is patient with one of the following pathology : Osteoporosis, Bone Fragility, articular inflammatory disease or Endocrine diseases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measure bone quality and quantity with HR-pQCT and DEXA of control group. Patient group is patient with episode of acute back pain or radicular pain</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HR-pQCT</intervention_name>
    <description>Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.
For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal.</description>
    <arm_group_label>Patient group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DEXA</intervention_name>
    <description>The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck</description>
    <arm_group_label>Patient group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. For patients:

             1.1.Women or Men taken in charge in Saint-Etienne' Hospital and one of the following
             pathologies: 1.1-a : Osteoporosis defined as: history of fracture by bone fragility
             documented 1.1-b : Bone Fragility: Patient with the indication of bone densitometry
             without a fracture history 1.1-c Articular inflammatory disease: Rheumatoid Arthritis,
             Spondyloarthritis 1.1-d Endocrine diseases : Primary Hyperparathyroidism,
             Constitutional Thinness, Anorexia nervosa 1.2. written consent

          2. For controls:

        2.1. Episode of acute back pain or radicular pain (lasting for less than a month) with
        taking corticosteroid less than 1 month 2.2. written consent

        Exclusion Criteria:

        drugs induced bone loss: 1.1.Anti-aromasine or GnRH agonist for at least 6 months, 1.2.
        Corticosteroid therapy 1.3. Antiepileptic carbamazepine, phenobarbital, phenytoin,
        primidone, valproic acid for at least 6 months) 2. fracture due to bone fragility 3. drug
        with bone effect (bisphosphonate, teriparatide, strontium ranelate)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Thomas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hubert Marotte, PhD</last_name>
    <phone>(0)477127643</phone>
    <email>hubert.marotte@chu-st-etienne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert Marotte, PhD</last_name>
      <phone>(0)477127643</phone>
      <phone_ext>+33</phone_ext>
      <email>hubert.marotte@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Thomas, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hubert Marotte, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Hélène Lafage-Proust, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adamah Amouzougan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Béatrice Pallot-Prades, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Collet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elodie Constant, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bogdan Galusca, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natacha Germain, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2015</study_first_submitted>
  <study_first_submitted_qc>August 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2015</study_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fracture osteoporosis</keyword>
  <keyword>bone microarchitecture</keyword>
  <keyword>Inflammatory joint diseases</keyword>
  <keyword>Bone fragility</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Spondyloarthritis</keyword>
  <keyword>Primary Hyperparathyroidism</keyword>
  <keyword>constitutional thinness</keyword>
  <keyword>anorexia nervosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

